title: Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches.
abstract: The current standard of care for metastatic urothelial carcinoma is cisplatin-based chemotherapy but treatment is generally not curative. Mechanisms of resistance to conventional cytotoxic regimens include tumor cell drug efflux pumps, intracellular anti-oxidants, and enhanced anti-apoptotic signaling. Blockade of signaling pathways with small molecule tyrosine kinase inhibitors has produced dramatic responses in subsets of other cancers. Multiple potential signaling pathway targets are altered in Urothelial carcinoma (UC). Blockade of the PI3K/Akt/mTOR pathway may prove efficacious because 21% have activating PI3K mutations and another 30% have PTEN inactivation (which leads to activation of this pathway). The fibroblast growth factor receptor 3 protein may be overactive in 50-60% and agents which block this pathway are under development. Blockade of multiple other pathways including HER2 and aurora kinase also have potential efficacy. Anti-angiogenic and immunotherapy strategies are also under development in UC and are discussed in this review. Novel therapeutic approaches are needed in UC. We review the various strategies under investigation and discuss how best to evaluate and optimize their efficacy.
authors: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College New York, NY, USA.
authors: Richard M
authors: RM
authors: Bambury
authors: Jonathan E
authors: JE
authors: Rosenberg
keywords: bladder cancer; chemotherapy; oncogenes; resistance mechanisms; urothelial cancer
references: BJU Int. 2005 May;95(7):1086-90
references: 15839938
references: Br J Haematol. 2011 Feb;152(4):367-79
references: 21219297
references: EMBO Mol Med. 2011 Nov;3(11):623-36
references: 21953712
references: Eur J Cancer. 2006 Jan;42(1):50-4
references: 16330205
references: Urol Res. 1999 Jun;27(3):157-63
references: 10422815
references: Semin Oncol. 2012 Oct;39(5):598-607
references: 23040256
references: J Pathol. 2007 Sep;213(1):91-8
references: 17668422
references: N Engl J Med. 2003 Mar 13;348(11):994-1004
references: 12637609
references: Lab Invest. 2010 Oct;90(10):1406-14
references: 20661228
references: N Engl J Med. 2010 Jul 29;363(5):411-22
references: 20818862
references: N Engl J Med. 2012 Nov;367(18):1694-703
references: 23020132
references: J Urol. 2001 Oct;166(4):1275-9
references: 11547057
references: Science. 2002 Jul 5;297(5578):63-4
references: 12098689
references: N Engl J Med. 2010 Aug 26;363(9):809-19
references: 20818844
references: J Immunother. 2008 Nov-Dec;31(9):849-57
references: 18833002
references: BJU Int. 2012 Dec;110(11 Pt C):E809-18
references: 22974436
references: PLoS One. 2010 Nov 03;5(11):e13821
references: 21072204
references: Anticancer Res. 2010 Jun;30(6):2145-52
references: 20651363
references: Cancer Res. 1988 Dec 15;48(24 Pt 1):7067-71
references: 3191483
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Eur Urol. 2010 Sep;58(3):433-41
references: 20646825
references: N Engl J Med. 2010 Aug 19;363(8):711-23
references: 20525992
references: J Clin Oncol. 2009 Dec 1;27(34):5680-4
references: 19858384
references: J Urol. 1994 Dec;152(6 Pt 2):2272-5
references: 7966723
references: J Clin Oncol. 2003 Apr 15;21(8):1431-9
references: 12668651
references: BJU Int. 2008 Aug 5;102(5):610-6
references: 18384625
references: Oncogene. 2007 Aug 30;26(40):5889-99
references: 17384684
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: BMC Cancer. 2012 Aug 15;12:354
references: 22894607
references: Int J Cancer. 2012 Mar 15;130(6):1357-66
references: 21500189
references: Ann Oncol. 2013 Apr;24(4):1011-7
references: 23136231
references: Clin Cancer Res. 2010 May 15;16(10):2861-71
references: 20460488
references: Eur Urol. 2011 Aug;60(2):344-9
references: 21645967
references: J Clin Oncol. 2011 Apr 20;29(12):1525-30
references: 21422406
references: Lancet Oncol. 2012 Aug;13(8):810-6
references: 22819172
references: Anticancer Res. 2012 Jun;32(6):2295-9
references: 22641665
references: Ann Oncol. 2010 Apr;21(4):815-819
references: 19889613
references: Expert Rev Vaccines. 2011 Jun;10(6):733-42
references: 21692696
references: Hum Mol Genet. 2013 Feb 15;22(4):795-803
references: 23175443
references: J Natl Cancer Inst. 1995 Nov 1;87(21):1603-12
references: 7563203
references: J Clin Oncol. 2011 Sep 1;29(25):3443-9
references: 21810677
references: N Engl J Med. 2011 Jun 30;364(26):2507-16
references: 21639808
references: Ann Oncol. 2012 Oct;23(10):2663-2670
references: 22473592
references: N Engl J Med. 2012 May 24;366(21):2038-40
references: 22621641
references: Int J Cancer. 2012 Aug 15;131(4):987-96
references: 21964864
references: Clin Cancer Res. 2004 Jul 15;10(14):4661-9
references: 15269138
references: Expert Rev Anticancer Ther. 2012 Feb;12(2):271-81
references: 22316374
references: Urol Oncol. 2013 Apr;31(3):303-11
references: 22285006
references: Cancer Lett. 1997 Nov 11;119(2):157-62
references: 9570366
references: Ann Oncol. 2007 Mar;18(3):522-8
references: 17229776
references: Food Chem Toxicol. 2012 May;50(5):1226-37
references: 22326969
references: Ann Oncol. 2011 Dec;22(12):2646-2653
references: 21427062
references: Mol Cancer Ther. 2007 Jan;6(1):299-308
references: 17218637
references: Science. 2012 Oct 12;338(6104):221
references: 22923433
references: Future Oncol. 2010 Jun;6(6):951-65
references: 20528233
references: J Clin Oncol. 2005 Jul 20;23(21):4602-8
references: 16034041
references: BJU Int. 2009 Feb;103(3):384-90
references: 19007378
references: PLoS One. 2012;7(12):e50786
references: 23226540
references: J Clin Oncol. 2000 Sep;18(17):3068-77
references: 11001674
references: J Clin Oncol. 2007 Jun 1;25(16):2218-24
references: 17538166
references: Cancer Res. 2000 Mar 1;60(5):1312-6
references: 10728692
references: J Thorac Oncol. 2012 Oct;7(10):e23-4
references: 22743296
references: N Engl J Med. 2012 Feb 9;366(6):520-9
references: 22149876
references: Int J Biol Markers. 2009 Jan-Mar;24(1):17-21
references: 19404918
references: Eur J Cancer. 2010 Jan;46(1):207-15
references: 19914824
references: J Clin Oncol. 2012 Apr 1;30(10):1107-13
references: 22370319
references: Adv Urol. 2012;2012:364919
references: 22400017
references: BJU Int. 2002 Jul;90(1):113-7
references: 12081782